B
Bullisch
Bullisch · 25%ALKS
$29.09
Szenariopreis
$40.100
+1.047 (+2.61%)Zum Schluss
Loading chart…
- Hoch
- 40.740
- Eröffnung
- 39.740
- Volumengewichteter Durchschnittskurs
- 40.09
- Volumen
- 1.98M
- Marktkap.
- 4.11B
- Tief
- 39.420
- Umsatz
- 79.24M
- EV/EBITDA, TTM
- 21.00
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy.
KI-Analyse of Alkermes Plc (ALKS)
HaltenAlkermes Plc is currently a hold. The stock is priced at $40.61, with a forward P/E ratio of 133.33, indicating high valuation expectations. Although the company has shown strong revenue growth of 27.5% year-over-year, recent insider selling and a low RSI of 38.997 suggest caution. The main risk is the significant drop in net income, which was -66.48 million USD in Q1 2026, indicating potential volatility ahead.
Analystenbewertungen (12)
+15.21% Aufwärtspotenzial
Halten
5 Kaufen
7 Halten
0 Verkaufen
Aktuell: 40.10
Tief
37.00
Durchschnitt
46.20
Hoch
58.00
Baird
Überdurchschnittlich
$61
2026-09-22
Baird
2026-09-22
Kursziel
$61
Überdurchschnittlich
H.C. Wainwright
Neutral
—
2026-09-21
H.C. Wainwright
2026-09-21
Kursziel
—
Neutral
Mizuho
Überdurchschnittlich
$65
2026-09-04
Mizuho
2026-09-04
Kursziel
$65
Überdurchschnittlich
JPMorgan
Neutral
$61
2026-07-29
JPMorgan
2026-07-29
Kursziel
$61
Neutral
Baird
Überdurchschnittlich
$58
2026-07-29
Baird
2026-07-29
Kursziel
$58
Überdurchschnittlich
Bewertungskennzahlen
Das aktuelle erwartete KGV von Alkermes Plc (ALKS) beträgt 133.33, verglichen mit dem 5-Jahres-Durchschnitt von 92.98.
Alphio-AI-Kursszenarien für ALKS
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die ALKS halten
Event-Zeitleiste
News
9.009-21NewsfilterALKS 7290 Shows Clinically Meaningful Improvements in Adult ADHD Symptoms
5.008-29NASDAQ.COMAlkermes Executive Sells 7,576 Shares, Reducing Holdings
5.008-29FoolAlkermes Executive Sells 7,576 Shares Amid Strong Performance
- 9.008-24Newsfilter
Alixorexton Shows Significant Improvements in Narcolepsy Treatment
- 9.507-28seekingalpha
Alkermes Q2 2026 Earnings Call Insights
ALKS FAQ – beantwortet von Alphio AI
Alkermes plc is an Ireland-based global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Its pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including attention-deficit hyperactivity disorder (ADHD) and fatigue associated with multiple sclerosis and Parkinson’s disease. The Company's pipeline includes Olanzapine and samidorphan, Alixorexton, ALKS 4510, ALKS 7290, and Valiloxybate. Its LUMRYZ (sodium oxybate) for extended-release oral suspension is a central nervous system depressant indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years of age and older with narcolepsy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Alkermes Plc is currently a hold. The stock is priced at $40.61, with a forward P/E ratio of 133.33, indicating high valuation expectations. Although the company has shown strong revenue growth of 27.5% year-over-year, recent insider selling and a low RSI of 38.997 suggest caution. The main risk is the significant drop in net income, which was -66.48 million USD in Q1 2026, indicating potential volatility ahead.
12 analysts cover ALKS: 5 rate it Buy, 7 Hold and 0 Sell. The average price target is 46.20.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.